Clinical Trial Update: Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing intranasal insulin to subcutaneous insulin for postprandial metabolism in Type 1 Diabetes Mellitus was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Intranasal insulin (insulin)
• Subcutaneous insulin (insulin)

Snippet

Sponsor: CPEX Pharmaceuticals Inc. | Conditions: Type 1 Diabetes Mellitus | Phase 2 | Status: WITHDRAWN